PCE is pleased to announce a new collaboration with OncoSil Medical as part of the ‘Treatment Opportunities for Pancreatic Cancer‘ project. The initiative aims to raise awareness of innovative therapies, address inequalities in access across Europe, and improve outcomes for patients.
Pancreatic cancer remains one of the deadliest cancers, with limited treatment options and significant disparities in access between countries. This project will highlight gaps in the treatment landscape, promote awareness of new therapies, and foster collaboration to advance equity in care.
OncoSil Medical will contribute its expertise in innovative therapies, working with PCE to ensure the patient voice remains central.
Nigel Lange, CEO & Managing Director of OncoSil Medical, shared:
“We are honoured to work with Pancreatic Cancer Europe on this important initiative. By collaborating, we can raise awareness, share knowledge, and help shape a future where more patients have access to life-changing therapies.”
Alfredo Carrato, Founder and Chairperson of PCE, also shared:
“Pancreatic cancer patients across Europe often face disparities in treatment. By joining forces with OncoSil Medical, we are combining expertise and resources to make a meaningful difference in patient care.”
Learn more here.